Galecto to Present Poster at Upcoming ATS 2023 International Conference
The poster, entitled: “The Anti-Fibrotic Effect of GB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices from Idiopathic Pulmonary Fibrosis Tissue,” showed GB0139 effected a concentration-dependent reduction in markers of fibrosis (Co1α1, hyaluronic acid, TIMP-1, MMP-7), in comparison to currently approved IPF therapies, pirfenidone and nintedanib.
GB0139 is an inhaled, small molecule inhibitor of galectin-3 and is currently being investigated in Galecto’s Phase 2b trial for the treatment of IPF (NCT03832946).
“We are very pleased to present additional data on our small molecule GB0139 at this prestigious conference, as it continues to validate and support our development in IPF,” said Hans Schambye, M.D., Ph.D., President and Chief Executive Officer of
Details for the poster presentation is as follows:
Title: The Anti-Fibrotic Effect of GB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices from Idiopathic Pulmonary Fibrosis Tissue
Session: A67- BIOMARKERS, MEDIATORS, AND TRANSLATIONAL MODELS FOR ILD
Date:
Time:
Location:
Following the poster session at the
About Galecto
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an inhaled galectin-3 modulator (GB0139) in a Phase 2b trial for the treatment of idiopathic pulmonary fibrosis; (ii) an orally active LOXL2 inhibitor (GB2064) in a Phase 2 trial for the treatment of myelofibrosis; (iii) an orally active galectin-3 inhibitor (GB1211) in a Phase 1b/2a trial in liver cirrhosis; and (iv) an orally active galectin-3 inhibitor (GB1211) in combination with atezolizumab (Tecentriq®) in a separate Phase 2 trial for the treatment of non-small cell lung cancer.
Galecto intends to use its website as a means of disclosing material non-public information. For regular updates about Galecto, visit www.galecto.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the tolerability and efficacy of galectin-1 and galectin-3 inhibitor product candidates. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements,
For more information, contact:
Hans Schambye, CEO | |
+45 70 70 52 10 | |
Investors/US | Media/EU |
arr@lifesciadvisors.com | svonderweid@lifesciadvisors.com |
+1 617 430 7577 | +41 78 680 0538 |

Source: Galecto, Inc.